Summary
For Year 2025-26, Gland Pharma reports the following shareholding: Total Promoters at 51.83%, Mutual Fund at 31.42%, Insurance at 1.33%, Foreign Institutional Investors at 7.58%, Domestic Institutional Investors at 0.23%, and Retail at 7.61%. This breakdown provides a quick snapshot of ownership distribution for Gland Pharma in 2025-26.
Gland Pharma FAQs
As of 03-2026, the promoter shareholding in Gland Pharma stands at 51.83% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Gland Pharma is 7.58% and 0.23% respectively.
The retail shareholding of the Gland Pharma is 7.61%.
Changes in shareholding patterns of Gland Pharma can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Gland Pharma are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
